Related references
Note: Only part of the references are listed.AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia
Todd M. Cooper et al.
CANCER (2012)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High Expression of the Very Late Antigen-4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Phoenix A. Ho et al.
BLOOD (2009)
On flow cytometry in myelodysplastic syndromes, with caveats
Denise A. Wells et al.
LEUKEMIA RESEARCH (2008)
The incidence and clinical significance of nucleophosmin mutations in childhood AML
Patrick Brown et al.
BLOOD (2007)
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
Roland B. Walter et al.
BLOOD (2007)
Clinical implications of FLT3 mutations in pediatric AML
Soheil Meshinchi et al.
BLOOD (2006)
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia
Jessica A. Pollard et al.
BLOOD (2006)
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
RJ Arceci et al.
BLOOD (2005)
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
RB Walter et al.
BLOOD (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
I Jedema et al.
LEUKEMIA (2004)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)
Gemtuzumab ozogamicin:: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis
CM Zwaan et al.
BLOOD (2003)
Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia
DL Johnston et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Differences in CD33 intensity between various myeloid neoplasms
I Jilani et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2002)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
Share Paper
